Robin Carhart-Harris, PhD, is a British psychologist and neuroscientist researching psychedelics and their efficacy in the treatment of major depression.
CLEAR ALL
REBUS and the Anarchic Brain: A Unified Model of the Brain Action of Psychedelics Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University.
1
These results support a recent model proposing that psychedelics reduce the ‘precision-weighting of priors’, thus altering the balance of top-down versus bottom-up information passing.
Abstract: Highlighting the results of two fMRI studies and one MEG study with psilocybin and an fMRI study with MDMA, Carhart-Harris will report the effects of both drugs on regional brain activity and brain network organization.
The scientists hope their long-awaited study on LSD in humans will open the floodgates to further research into psychedelics.
How could LSD and psilocybin help with mental health, palliative care and addictive behaviours? What was the point of a psilocybin mushroom evolving the way that it did? Michael Pollan explores the “second wave” of international research and discusses what psychedelic drugs may teach us about...
For a long time, research into flow states was subjective—researchers had to rely on people’s self-reported experiences to understand altered states of mind.
Robin has been conducting pioneering brain imaging studies of psychedelic drugs. Most recently, he has completed the first phase of a clinical trial looking at the potential of psilocybin to treat depression, and his talk looks at how these drugs can be used in treatment.
At Imperial College we’ve been comparing psilocybin to conventional antidepressants—and the results are likely to be game-changing.
Can LSD and psilocybin provide relief to people suffering from difficult-to-treat conditions such as depression and anxiety? Robin Carhart-Harris is a neuroscientist and head of the Imperial Centre for Psychedelic Research, which builds on over a decade of pioneering work psychedelic research,...
In a recent UK trial, 12 patients with major depression took a pill quite different to commonly prescribed antidepressants: 25mg of psilocybin, the psychedelic compound found in magic mushrooms.
Photo Credit: Photograph by Thomas Angus, Imperial College London / Distributed under the CC BY-SA 4.0
